Detalhe da pesquisa
1.
Challenges and recent progress in drug discovery for tropical diseases.
Nature
; 559(7715): 498-506, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30046073
2.
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Nature
; 560(7717): 192-197, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30046105
3.
Author Correction: Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis.
Nature
; 619(7970): E48, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37402863
4.
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Proc Natl Acad Sci U S A
; 116(19): 9318-9323, 2019 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30962368
5.
Trypanosoma cruzi Phosphomannomutase and Guanosine Diphosphate-Mannose Pyrophosphorylase Ligandability Assessment.
Antimicrob Agents Chemother
; 63(10)2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31405854
6.
Identification of Novel Trypanosoma cruzi Proteasome Inhibitors Using a Luminescence-Based High-Throughput Screening Assay.
Antimicrob Agents Chemother
; 63(9)2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31307977
7.
2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' disease.
Bioorg Med Chem Lett
; 28(18): 3025-3030, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30104093
8.
Comment on "The translational challenge in Chagas disease drug development" by Kratz et al.
Mem Inst Oswaldo Cruz
; 117: e210501chgsb, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35613160
9.
ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.
J Cell Sci
; 126(Pt 11): 2381-91, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23549785
10.
Validation of Trypanosoma cruzi inactivation techniques for laboratory use.
PLoS One
; 19(4): e0300021, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635818
11.
Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity.
PLoS Negl Trop Dis
; 18(2): e0011956, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38359089
12.
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.
Antimicrob Agents Chemother
; 57(7): 2913-22, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23571538
13.
The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.
Antimicrob Agents Chemother
; 57(10): 4699-706, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23856774
14.
Anti-trypanosomatid drug discovery: progress and challenges.
Nat Rev Microbiol
; 21(1): 35-50, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35995950
15.
Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static-Cidal Screening of Analogues.
J Med Chem
; 66(13): 8896-8916, 2023 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37343180
16.
Short-course combination treatment for experimental chronic Chagas disease.
Sci Transl Med
; 15(726): eadg8105, 2023 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38091410
17.
Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma cruzi Proteasome Inhibitors.
J Med Chem
; 66(15): 10413-10431, 2023 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506194
18.
Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.
Eur J Med Chem
; 238: 114421, 2022 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35594652
19.
Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay.
PLoS Negl Trop Dis
; 15(10): e0009870, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34634052
20.
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
J Med Chem
; 64(9): 5905-5930, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33904304